A Phase III study (NCT03656536) comparing pemigatinib vs. GemCis in treatment-naïve patients with unresectable or metastatic CCA harboring FGFR2 fusions or rearrangements is currently ongoing. This evidence concerns the gene FGFR2 and cholangiocarcinoma.